This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).  

This study investigated the occurrence of fatigue (tiredness) in patients with early rheumatoid arthritis (RA) and identified predictors of fatigue after 24 months. The data showed that patients with early disease remission had a rapid, sustained reduction in fatigue and that low disease activity at diagnosis predicted a higher risk of fatigue at 24 months.

This study looked at the use of peficitinib (Smyraf) for the treatment of rheumatoid arthritis (RA) from the perspective of patients and their doctors. It found that peficitinib improved symptoms of RA and led to increased ability to work and carry out daily activities compared to placebo.

This study examined the association of physical activity (PA) and sedentary time (ST) with pain, fatigue, and depressive symptoms over time among survivors of breast cancer (BC). The data showed that lower ST and higher PA is associated with lower depressive symptoms in long-term survivors of BC.

This study evaluated the occurrence and clinical predictors of peripheral neuropathy (PN; nerve damage) in long-term survivors of breast cancer (BC). The data showed that PN is an important long-term consequence of taxane-based chemotherapy in survivors of BC.

This study explored the risk factors for fragility fractures in patients with rheumatoid arthritis (RA). The authors concluded that aging, disease-related factors, and previous fracture history are important risk factors for fragility fractures in these patients.

This study investigated the relationships among depression and anxiety, diet, and disease activity or physical function in patients with rheumatoid arthritis (RA). The data showed that there was a relationship between depression and lower fish intake frequency in these patients. 

This study evaluated the benefits of denosumab (Xgeva) on the bone health of women with early-stage breast cancer (BC). The data showed that denosumab improved bone-related outcomes in women with high-risk early-stage BC

This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients.

This study compared the effectiveness and safety of tofacitinib (Xeljanz) and baricitinib (Olumiant) in patients with rheumatoid arthritis in a real-world setting. The data showed that tofacitinib and baricitinib had similar effectiveness and safety but clinical responses may depend on previous use of anti-rheumatic drugs.